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Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allo-
geneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve out-
comes. We conducted a phase II study of busulfan (.8 mg/kg i.v. twice daily on days 5, 4, 3, and 2) with
clofarabine (40 mg/m2 i.v. daily on days 5, 4, 3, and 2) conditioning before allogeneic 8/8 HLAematched
related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day þ40. Secondary
endpoints included nonrelapse mortality (NRM), acute and chronic graft-versus-host disease (GVHD),
progression-free survival (PFS), and overall survival (OS). Thirty-four patients (acute myeloid leukemia [AML],
n ¼ 25; myelodysplastic syndromes, n ¼ 5; and acute lymphoid leukemia, n ¼ 4) were enrolled. Day 40þ
engraftment with donor chimerism was achieved in 33 of 34 patients with 1 patient dying before count
recovery. Day 100 and 1-year NRM were 5.9% (95% conﬁdence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to
39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and
chronic GVHD were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and OS was 56% (95%
CI, 38 to 71). For patients with AML in ﬁrst complete remission, 2-year PFS and OS were both 82% (95% CI, 55
to 94). RIC with busulfan and clofarabine leads to successful engraftment with acceptable rates of NRM and
GVHD.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION HSCT for many patients who are older or possess signiﬁcant
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative treatment for many patients with acute
leukemia and myelodysplastic syndrome (MDS) [1,2]. The
therapeutic mechanisms of HSCT lie in the cytotoxicity of the
conditioning regimen and an immunological graft-versus-
leukemia effect from donor cell reactivity against host
malignant cells [3]. The advent of reduced-intensity condi-
tioning (RIC) regimens has allowed the safe application ofedgments on page 84.
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ty for Blood and Marrow Transplantation.comorbidities [3-5]. Indeed, HSCT has become an increas-
ingly accepted standard for consolidation therapy for older
patients with acute myeloid leukemia (AML) in ﬁrst remis-
sion [6,7] and ongoing trials are deﬁning its application in
older patients with acute lymphoid leukemia (ALL) andMDS.
Although the term RIC is used to describe regimens that do
not fully ablate host hematopoiesis and consensus deﬁni-
tions have been established, the intensity of RIC regimens
varies greatly [8].
Despite reliable rates of engraftment in patients receiving
RIC HSCT, disease relapse remains the leading cause of long-
term patient mortality [4]. Historically, conditioning regimen
dose intensity has appeared to play a role in reducing rates of
disease relapse, albeit at the expense of increasing toxicity.
Indeed, in prior studies comparing myeloablative versus RIC
Table 1
Participant Characteristics
Characteristic Value
n %
Age, median (range), yr 34 (25-74) 63.5
Gender (male) 25 74
Diagnosis
AML 25 74
MDS 5 15
ALL 4 12
HCT-DRI
Low 1 3
Intermediate 27 79
High 6 18
Disease stage
CR1 25 74
CR2 6 18
Partial remission/active disease/blasts >5% 3 9
Cytogenetics
AML/MDS*
Favorable 1
Intermediate 24
Adverse 5
ALL
Philadelphia chromosome 2
Other 2
HCT-CI, median (range) 34 1 (0-9)
Donor type
Matched related 11 32
Matched unrelated 23 68
Female donor-male recipient 9 26
CMV serostatus
Either donor/hostþ 22 65
Both negative 12 35
CMV indicates cytomegalovirus.
* Southwest Oncology Group risk stratiﬁcation.
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with general trends of decreased nonrelapse mortality
(NRM) with RIC, but with a higher rate of relapse [9-11],
although there are some conﬂicting reports. Using RIC regi-
mens with more potent agents may be able to reduce relapse
rates while maintaining acceptable rates of NRM.
Clofarabine is a novel purine nucleoside analogue that has
shown activity both as a single agent and in combination
with other agents in heavily pretreated, relapsed refractory
patients with AML and ALL [12,13]. Given clofarabine’s
reasonable toxicity proﬁle and similar mechanism of action
to ﬂudarabine, several recent studies have substituted clo-
farabine in place of ﬂudarabine in melphalan-based RIC
regimens for HSCT [14,15]. In addition, in vitro studies have
demonstrated a synergistic cytotoxicity of clofarabine in
combination with busulfan [16]. Therefore, we conducted a
phase II study of RIC with busulfan and clofarabine for pa-
tients with AML, ALL, and MDS undergoing matched related
or unrelated peripheral blood stem cell (PBSC) trans-
plantation in an effort to improve antileukemic activity
without added toxicity.
METHODS
Patients
This study was approved by the institutional review board at the Dana-
Farber Harvard Cancer Center and conducted at Dana-Farber Brigham &
Women’s Cancer Center and Massachusetts General Hospital Cancer Center.
Informed consent was obtained from all patients and the trial was registered
at ClinicalTrials.gov (NCT01643668). Adult patients with AML, ALL, or MDS
were eligible. For patients with ALL or AML, bone marrow blasts were <5%,
whereas for patients with MDS, bone marrow blasts were <10%. Patients
with low-, intermediate-, or high-risk disease based on the Disease Risk
Index (DRI) were eligible to participate [17]. All patients had an Eastern
Cooperative Oncology Group performance status score of 0 to 2, a left ven-
tricular ejection fraction  40%, adequate pulmonary function tests (forced
expiratory volume in 1 second [FEV1], forced vital capacity [FVC], and
diffusion capacity corrected for hemoglobin level [DLCO] all 50% of pre-
dicted), total serum bilirubin< 2.0mg/dL, and serum creatinine< 2.0mg/dL.
Conditioning Regimen
We used RIC with clofarabine and busulfan. Clofarabine 40 mg/m2 was
given daily on days 5, 4, 3, and 2 intravenously over approximately 60
minutes. The dosage was based on the patient’s body surface area, calculated
using the actual height and weight before the start of conditioning. We
administeredbusulfan0.8mg/kg intravenously twicedailyondays5,4,3,
and2 over approximately 2 hours. Busulfanwas dosed based on actual body
weight and busulfan pharmacokinetics were not measured. Busulfan
wasadministeredafterclofarabineandthebusulfandosesweregiven12hours
apart. In conjunction with chemotherapy, patients received prehydration,
standard antiemetics, and intravenous ﬂuids as needed.
Donors, Graft-versus-Host Disease Prophylaxis, and Supportive Care
Donors were 8/8 matched (HLA-A, -B, -C, and -DRB1 by allele-level
typing) related or unrelated donors. PBSCs were mobilized with gran-
ulocyte colonyestimulating factor and collected with standard apheresis
procedures. All participants received tacrolimus and low-dose methotrexate
(5 mg/m2 i.v. on days 1, 3, and 6 after HSCT) for graft-versus-host disease
(GVHD) prophylaxis. The administration of antithymocyte globulin was not
permitted in this study. Participants started tacrolimus on day 3 and
continued in therapeutic range (trough 5 to 10 ng/mL) until day þ90, when
if no active GVHD were present, immunosuppression taper was initiated
with a goal of discontinuation by day þ180. Prophylaxis against herpes
simplex/varicella zoster virus and Pneumocystis jirovecii infections was
continued through at least 1 year after HSCT. Cytomegalovirus viral loads
were routinely monitored and pre-emptive treatment was given for sig-
niﬁcant reactivation. Granulocyte colonyestimulating factor at a dose of 300
mg was administered subcutaneously daily from day þ7 until the absolute
neutrophil count was >1000/mL for 2 consecutive days or >5000/mL.
Disease Risk and Comorbidities
We utilized the DRI [17] to classify patients’ diseases and the Hemato-
poietic Stem Cell Transplantation-Comorbidity Index (HCT-CI) to assess
comorbidities at the time of enrollment into the study [18].Engraftment and GVHD
We deﬁned neutrophil engraftment as the ﬁrst day of an absolute
neutrophil count  500/mL on 3 consecutive measurements. We deﬁned
platelet recovery as the ﬁrst day of 2 consecutive measurements of platelets
 20,000/mL, independent of transfusion support. We assessed chimerism at
30 and 100 days after transplantation. Chimerismwas assessed with the use
of single-locus microsatellite DNA probes using PCR unless XX/XY ﬂuores-
cein in situ hybridization analysis was informative. Full donor chimerismwas
deﬁned as having <5% recipient DNA. Acute GVHD was graded based on
consensus grading criteria [19], and cumulative incidence of acute GVHD
was calculated through day þ180 after HSCT. Chronic GVHD was graded by
the National Institutes of Health consensus criteria [20] with cumulative
incidence calculated through 12 months.Statistical Analysis
We used descriptive statistics to summarize patient characteristics,
using proportions for categorical variables and means or medians for
continuous variables depending on the normality of their distributions. We
constructed cumulative incidence curves for acute and chronic GVHD out to
180 days and 1 year, respectively, with competing risks of death and relapse.
Additional incidence curves were constructed for relapse and NRM using
Gray’s method [21]. Time to relapse and time to nonrelapse death were
measured from the date of stem cell infusion. OS and progression-free
survival (PFS) were calculated using the Kaplan-Meier method. OS was
deﬁned as the time from stem cell transplantation to death from any cause.
PFS was deﬁned as the time from stem cell transplantation to relapse, dis-
ease progression, or death from any cause.RESULTS
Patient and Transplantation Characteristics
Table 1 depicts patient and transplantation characteris-
tics. We enrolled 34 participants between July 1, 2012 and
August 20, 2013. The median age was 63.5 (range, 25 to 74),
and 74% (n ¼ 25), 15% (n ¼ 5), and 12% (n ¼ 4) of participants
had a diagnosis of AML, MDS, and ALL, respectively. The
median HCT-CI score was 1 (range, 0 to 9). Based on the DRI,
Table 2
Neutrophil and Platelet Engraftment
Outcome All
n % or days
No neutrophil nadir <500/mL 0 0
Neutrophil engraftment, median (range), d 33 11 (6-17)
No platelet nadir <20,000/mL 5 15
Platelet engraftment, median (range), d 27 13 (8-16)
Graft failure 0 0
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Figure 1. Cumulative incidence of NRM and relapse.
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intermediate-, and high-risk disease. Themajority of patients
(68%, n¼ 23) received a transplant from amatched unrelated
donor, and (32%, n ¼ 11) received a graft from a matched
related donor.
Engraftment
One participant experienced early death before engraft-
ment. Among the remaining 33 evaluable participants, 100%
achieved engraftment with a median time to neutrophil
engraftment of 11 (range, 6 to 17 days) and median time to
platelet engraftment of 13 (range, 8 to 16) days (Table 2). Five
participants did not experience a platelet nadir < 20,000/mL.
There were no cases of secondary graft failure. Full donor
chimerism was documented in 100% (n ¼ 33) and 85% (n ¼
28 of 33) of participants at day þ30 and þ100 after trans-
plantation, respectively. Two patients relapsed before 100
days and did not have 100-day chimerism analysis and 3
evaluable participants were missing day 100 chimerism
analysis.
Toxicity and NRM
Forty-one percent (n ¼ 14) of patients experienced non-
hematological grade 3 or 4 toxicities (Table 3). The most
common grade 3 or 4 toxicity was bacterial infection
affecting 29% of participants, with 2 participants developing
septic shock. Transient grade 3 or 4 liver function abnor-
malities were seen in 9% (n ¼ 3) of participants. One
participant experienced grade 3 mucositis. There were no
cases of idiopathic pneumonia syndrome, diffuse alveolar
hemorrhage, or hepatic sinusoidal obstruction syndrome.
Other grade 3 or 4 toxicities included febrile neutropenia (6%,
n ¼ 2) and acute renal failure (3%, n ¼ 1).Table 3
Grade 3 and 4 Toxicities
Grade 3 and 4 Toxicities All
n %
Infections
Bacterial 10 29
Viral 1 3
Fungal 2 6
Veno-occlusive disease 0 0
Mucositis 1 3
LFT abnormalities
Increased bilirubin 1 3
Increased ALT 1 3
Increased AST 1 3
DAH/IPS 0 0
Engraftment syndrome 0 0
Febrile neutropenia 2 6
Sepsis 1 3
Acute renal failure 1 3
LFT indicates liver function tests; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; DAH, diffuse alveolar hemorrhage; IPS, idio-
pathic pneumonia syndrome.Figure 1 depicts the cumulative incidence of NRM. The
100-day and 1-year rates of NRM were 5.9% (95% conﬁdence
interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respec-
tively (Table 4). There were a total of 15 deaths on study with
7 deaths (47%) attributable to disease relapse. Among the 8
deaths attributable to NRM, 4 were patients with MDS, ac-
counting for 80% of the participants with MDS enrolled in
this study, all of whom were older than 65 years and had an
HCT-CI score  4. The median HCT-CI score for all those
experiencing NRM was 4.5 (range, 1 to 8). Among the 8
deaths from NRM causes, 4 patients died because of GVHD, 2
because of septic shock, and 2 because of multiorgan failure.Acute and Chronic GVHD
Table 4 depicts the incidence of acute and chronic GVHD.
The cumulative incidence of grades II to IV acute GVHD at day
180 was 21% (95% CI, 8.9 to 35.6). Grades III and IV acute
GVHD occurred in 12% (95% CI, 3.6 to 25.1) by day 180. At 1
year, the cumulative incidence of chronic GVHD was 44%
(95% CI, 27 to 60). Of the 16 patients with chronic GVHD, 3
developed moderate chronic GVHD and only 1 participant
developed severe disease.Table 4
GVHD, NRM, Relapse, PFS, and OS Outcomes
Outcomes Estimate (95% CI)
Grades II-IV acute GVHD by day þ100 21% (8.9-35.6)
Grades III-IV acute GVHD by day þ100 12% (3.6-25.1)
Chronic GVHD by 1 year 44% (27-60)
NRM
100 Days 5.9% (1.0-17.4)
1 Year 24% (13-39)
Relapse
1 Year 21% (9.0-36.0)
2 Year 26% (13-42)
PFS
1 Year 50% (32-65)
2 Year 50% (32-65)
OS
1 Year 56% (38-71)
2 Year 56% (38-71)
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With a median follow-up of 20 months, the rates of dis-
ease relapse at 1 and 2 years were 21% (95% CI, 9 to 36) and
26% (95% CI, 13 to 42), respectively (Table 4, Figure 1). The 2-
year rates of OS and PFS were 56% (95% CI, 38 to 71) and 50%
(95% CI, 32 to 65), respectively (Figure 2). Among the 17
patients with AML in ﬁrst complete remission (CR1), the 2-
year PFS and OS were both 82% (95% CI, 55 to 94).DISCUSSION
Over the past 15 years, the use of RIC regimens before
HSCT has dramatically increased [4]. Although we now have
the ability to offer a potentially curative HSCT procedure to
an older and less ﬁt population of patients, the range of in-
tensity among these RIC regimens is quite broad. Although
past studies have suggested that there is a beneﬁt in terms of
disease control from increased cytotoxicity in traditional
myeloablative regimens, this is often offset by the increased
mortality from therapy-related complications [9-11]. It is
unclear if less drastic increases in the intensity of condi-
tioning can yield better disease control without accruing
more toxicity.
In this phase II trial, we sought to investigate the effect of
substituting clofarabine for ﬂudarabine in our standard
busulfan-based RIC regimen (busulfan 0.8 mg/kg i.v. twice
daily and ﬂudarabine 30 mg/m2 i.v. once daily on
days 5, 4,3, and2) [22] for patients with MDS or acute
leukemia undergoing RIC PBSC transplantation from
matched related or unrelated adult donors. Our results show
that this clofarabine and busulfan RIC regimen is safe with a
manageable toxicity proﬁle and acceptable NRM in patients
with acute leukemia. Furthermore, the regimen yields
excellent engraftment, with rates of acute and chronic GVHD
that are comparable to other RIC regimens. Notably, this
combination showed promising preliminary efﬁcacy in pa-
tients with AML in CR1 with 2-year PFS and OS both at 82%,
albeit with small numbers that require further validation in
larger studies. In contrast, 4 of the 5 patients with MDS (all of
whom were older than 65 with signiﬁcant comorbidities)
died from NRM causes, suggesting that this may not be the
optimal conditioning regimen for such patients.0.
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Figure 2. PFS and OS.Studies have previously investigated the role of busulfan
combined with clofarabine as a myeloablative conditioning
regimen for allogeneic HSCT in patients with various hema-
tologic malignancies [23-26]. These studies have shown an
encouraging safety proﬁle with the most common grade 3
and 4 toxicities being transient transaminitis, mucositis,
hand/foot syndrome, hyperbilirubinemia, and hepatic sinu-
soidal obstruction syndrome [25]. Although our study is the
ﬁrst to report on the use of busulfan and clofarabine in the
RIC setting, clofarabine has been utilized in combination
with other agents in early phase I/II studies as RIC [14,15]. In a
phase I study combining clofarabine with melphalan for RIC
HSCT in patients with AML,100% of patients engrafted by day
30, 12.5% experienced NRM at 100 days, and 25% developed
grades II to IV acute GVHD [14]. In another phase I/II trial
involving 24 patients treated with a RIC regimen comprising
clofarabine, melphalan, and alemtuzumab, patients achieved
100% engraftment with acceptable toxicities [15]. Our ﬁnd-
ings with the combination of clofarabine and busulfan
showed relatively lower rates of NRM at 100 days and a
similarly encouraging safety proﬁle and preliminary efﬁcacy
among patients with acute leukemia. Although these ﬁnd-
ings are promising, prospective clinical trials comparing
various RIC regimens are critically needed to fully answer the
question of whether an optimal RIC regimen exists that
maximizes antileukemic activity and minimizes NRM.
Prior studies with escalating-dose intensity of the con-
ditioning regimen have shown improvement in relapse
rates at the expense of higher toxicity and NRM. In fact,
retrospective comparisons of traditional myeloablative reg-
imens to RIC regimens have historically shown decreased
rates of transplantation-related mortality at a cost of
increased disease relapse for RIC regimens, resulting in
comparable rates of overall survival [10,11,27-29]. More
recent series have suggested that dose intensity of mye-
loablative conditioning can be partially decreased, thereby
lowering associated toxicity, without sacriﬁcing efﬁcacy
[30,31]. Bornhauser et al. conducted a prospective phase III
randomized trial in 195 patients with AML in CR1 under-
going allogeneic HSCT, comparing a lower-intensity regimen
(ﬂudarabine þ 800 cGy of total body irradiation [TBI]) to a
conventional myeloablative conditioning regimen (120 mg/
kg of cyclophosphamide þ 1200 cGy TBI). Results showed
similar rates of GVHD, NRM, relapse, PFS, and OS; however,
the RIC regimen clearly had less overall toxicity [30]. A
recent Bone Marrow Transplant Clinical Trials Network
(BMT CTN 0901) protocol randomized patients with MDS or
AML to several RIC versus myeloablative conditioning regi-
mens (ClinicalTrials.gov ID NCT01339910) to try to deﬁni-
tively answer this question. However, this study was closed
before completing accrual, and deﬁnitive results have not
yet been released.
In the RIC setting, there have been 2 recent prospective
trials comparing different conditioning regimens. In-
vestigators in Germany randomized 139 patients with
various hematological malignancies to receive a busulfan
and ﬂudarabine regimen (busulfan 4 mg/kg/day orally 
2 days with ﬂudarabine) versus ﬂudarabine and TBI (ﬂu-
darabine with 200 cGy TBI). All grafts were from matched
related donors. Acute GVHD was higher after busulfan and
ﬂudarabine, but the incidence of chronic GVHD was similar
between the 2 groups. NRM was higher after busulfan and
ﬂudarabine (38% versus 22%), but the rate of disease relapse
was lower, leading to comparable rates of overall survival at 5
years after HSCT [32]. Baron et al. compared the combination
A. El-Jawahri et al. / Biol Blood Marrow Transplant 22 (2016) 80e8584of ﬂudarabine and melphalan versus ﬂudarabine and
busulfan in patients with AML undergoing matched related
donor HSCT. Once again, the more intense regimen (ﬂudar-
abine and melphalan) showed lower relapse rates, but there
was a trend towards higher NRM, leading to similar survival
outcomes [33]. Therefore, it remains unclear whether
modulating conditioning dose intensity to achieve better
cytotoxic activity without the added expense of higher NRM
is a reasonable therapeutic goal when attempting to improve
outcomes in patients with hematologic malignancies un-
dergoing allogeneic HSCT.
Future investigation should continue the efforts to opti-
mize RIC regimens by using active agents in doses that can
achieve reliable engraftment and cytotoxicity, while mini-
mizing complications. Certainly, prospective randomized
trials will be required to deﬁnitively answer such questions
and these analyses should also include other nontraditional
outcomes, such as cost and quality of life, both of which have
not been well studied in such analyses to date. Moreover,
careful attention should be given to the interaction between
the underlying disease and the conditioning regimen, as
some regimens may appear more toxic in patients with
certain diagnoses. However, it is uncertain if such modiﬁca-
tions in conditioning regimens will have a signiﬁcant effect
on overall HSCT outcomes when compared to other in-
novations being actively investigated to reduce disease
relapse after HSCT.
In conclusion, we demonstrate the safety and preliminary
efﬁcacy of the combination of busulfan and clofarabine as RIC
for patients with acute leukemia. Notably, the toxicity proﬁle
with this regimen was tolerable with 100 day and 1-year
NRM rates of 5.9% and 24%, respectively. Moreover, the in-
cidences of acute and chronic GVHD were comparable to
those seen with other conditioning regimens in the RIC
setting. Although the preliminary efﬁcacy is very promising
especially among patients with AML in CR1 treated with this
regimen, we observed higher and unacceptable NRM in older
patients with MDS and signiﬁcant comorbidities. In sum-
mary, clofarabine and busulfan is a reasonable RIC regimen to
consider for future comparative prospective studies with
the hopes of optimizing antileukemic activity without
compromising NRM, but caution should be exercised when
considering its use for elderly patients with signiﬁcant
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